Skip to main content
OpenTrials

Clinical trial condition

Ovarian Cancer

Explore clinical trials studying Ovarian Cancer. Study availability and eligibility vary by location and protocol.

1,470 public trials 326 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Cancer trial results

Recruiting

Evaluation of XYA02 in Patients With Advanced Solid Tumors

NCT07670312

Conditions
Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +38 more
Locations
  • Chris O'Brien Life House Sydney, New South Wales, Australia
  • Westmead Hospital Sydney, New South Wales, Australia
  • Monash Medical Centre Melbourne, Victoria, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

DESTINY-PANTUMOUR04

NCT07124000

Conditions
Adenocarcinoma, Adenocarcinoma (NOS), Adnexal Diseases, +116 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Bullhead City, Arizona, United States
  • Research Site Casa Grande, Arizona, United States
  • Research Site San Diego, California, United States
View all 18 locations
View Trial Details
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +65 more
Locations
  • Banner Health Gilbert, Arizona, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California San Diego La Jolla, California, United States
View all 16 locations
View Trial Details
Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT06799065

Conditions
Adnexal Diseases, Advanced Solid Tumors, Breast Cancer Recurrent, +24 more
Locations
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • Sarah Cannon Research Institute at HealthONE /ID# 278785 Denver, Colorado, United States
  • University of Chicago Medical Center /ID# 278295 Chicago, Illinois, United States
  • NEXT Oncology - San Antonio /ID# 278606 San Antonio, Texas, United States
  • Start Mountain Region /ID# 278609 West Valley City, Utah, United States
View all 22 locations
View Trial Details
Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326

Conditions
Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +25 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • The City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • Chao Family Comprehensive Cancer Center Orange, California, United States
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
View all 28 locations
View Trial Details
Recruiting

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

NCT07776691

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • MedStar Washington Hospital Center ( Site 0026) Washington D.C., District of Columbia, United States
  • Texas Oncology - DFW ( Site 8005) Fort Worth, Texas, United States
  • Sourasky Medical Center ( Site 1403) Tel Aviv, Israel
View Trial Details
Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT07059845

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • UC San Diego Health - Moores Cancer Center /ID# 277574 La Jolla, California, United States
  • Sansum Clinic - Solvang /ID# 277712 Solvang, California, United States
  • University of Florida College of Medicine /ID# 278348 Gainesville, Florida, United States
  • Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623 Orlando, Florida, United States
View all 84 locations
View Trial Details

Related conditions